上海
從破解耐藥到前移應用，埃萬妥單抗重塑晚期NSCLC治療全程格局。
*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。
參考文獻：
[1]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.
[2]Shih JY, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.
[3]entzler RD, et al. Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2. ELCC Congress 2024, 3MO.
[4]Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.
[5]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?) Non-Small Cell Lung cancer. Version 3. 2025.
[6]中國臨床腫瘤學會（CSCO）非小細胞肺癌診療指南（2025年）.
[7]Spira AI, Paz-Ares L, Han JY, et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr,a Phase 2 Study:A Brief Report.J Thorac Oncol. Published online January 24,2025.
審批編碼：CP-556187
批準分發(fā)日期：12/6/2025
有效期：12/6/2026
*“醫(yī)學界”力求所發(fā)表內(nèi)容專業(yè)、可靠，但不對內(nèi)容的準確性做出承諾；請相關各方在采用或以此作為決策依據(jù)時另行核查。
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺“網(wǎng)易號”用戶上傳并發(fā)布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
